Rapidly progressive glomerulonephritis after introduction of certolizumab pegol: a case report

References

• Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medecine (Baltimore). 2007;86:242–251.
   PubMed Web of Science ®Google Scholar
• Bruzzese V, Marrese C, Scolieri P, et al. Myasthenia gravis onset during rheumatic disease: a new paradoxical effect of anti-TNF alpha therapy? Int J Rheum Dis. 2015;18:375–376.
   Web of Science ®Google Scholar
• Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep. 2017;17:36.
   PubMed Web of Science ®Google Scholar
• Alkhunaizi AM, Dawamneh MF. ANCA-positive crescentic glomerulonephritis in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor alpha. Int J Rheum Dis. 2017;20:1843–1847.
   Google Scholar
• Doulton TW, Tucker B, Reardon J, et al. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol. 2004;62:234–238.
   PubMed Web of Science ®Google Scholar
• Hirohama D, Hoshino J, Hasegawa E, et al. Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-α. Mod Rheumatol. 2010;20:602–605.
   PubMed Web of Science ®Google Scholar
• Ashok D, Dubey S, Tomlinson I. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab. Clin Rheumatol. 2008;27:261–264.
   PubMed Web of Science ®Google Scholar
• Kaneko K, Nanki T, Hosoya T, et al. Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis. Mod Rheumatol. 2010;20:632–636.
   PubMed Web of Science ®Google Scholar
• Tosovský M, Bradna P, Laco J, et al. Case 1-2012: ANCA associated glomerulonephritis in combination with IgG4-positive mediastinal mass in a patient with ankylosing spondylitis treated with TNF alpha inhibitors. Acta Medica (Hradec Kralove). 2012;55:42–46.
   Google Scholar
• Reitblat T, Reitblat O. Appearance of ANCA – associated vasculitis under tumor necrosis factor-alpha inhibitors treatment. Am J Case Rep. 2013;14:80–82.
   Google Scholar
• Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20:1400–1406.
   PubMed Web of Science ®Google Scholar
• Parekh K, Ching D, Rahman MU, et al. Onset of Wegener’s granulomatosis during therapy with golimumab for rheumatoid arthritis: a rare adverse event? Rheumatology (Oxford). 2010;49:1785–1787.
   Web of Science ®Google Scholar
• Broshtilova V, Iliev E, Gantcheva M. Etanercept-induced Wegener granulomatosis in a patient with rheumatoid arthritis. Dermatol Ther. 2013;26:73–76.
   Web of Science ®Google Scholar
• Simms R, Kipgen D, Dahill S, et al. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. Am J Kidney Dis. 2008;51:e11–e14.
   PubMed Web of Science ®Google Scholar
• Ortiz-Sierra MC, Echeverri AF, Tobón GJ, et al. Developing of granulomatosis with polyangiitis during etanercept therapy. Case Rep Rheumatol. 2014;2014:210108.
   PubMedGoogle Scholar
• Omura Y, Haranaka M, Imada C, et al. Microscopic polyangiitis in a patient receiving TNF-α inhibitor therapy for rheumatoid arthritis. Kyushu J Rheumatol. 2016;36:27–33. Japanese.
   Google Scholar
• Csernok E. Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides. Autoimmun Rev. 2003;2:158–164.
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Krumbholz M, Schönermarck U, et al. Netting neutrophils in autoimmune small-vessel sel vasculitis. Nat Med. 2009;15:623–625.
   PubMed Web of Science ®Google Scholar
• Nakazawa D, Shida H, Tomaru U, et al. Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. J Am Soc Nephrol. 2014;25:990–997.
   PubMed Web of Science ®Google Scholar
• Grayson PC, Kaplan MJ. At the Bench: Neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases. J Leukoc Biol. 2016;99:253–264.
   Web of Science ®Google Scholar
• Guillevin L, Mouthon L. Tumor necrosis factor-alpha blockade and the risk of vasculitis. J Rheumatol. 2004;31:1885–1887.
   PubMed Web of Science ®Google Scholar
• Palucka AK, Blanck JP, Bennett L, et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA.. 2005;102:3372–3377.
   PubMed Web of Science ®Google Scholar
• de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143:223–231.
   PubMed Web of Science ®Google Scholar
• De Bandt M. Anti-TNF-alpha-induced lupus. Arthritis Res Ther. 2019;21:235.
   Web of Science ®Google Scholar
• Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011;3:73ra19.
   PubMed Web of Science ®Google Scholar
• Jones RB, Tervaert JW, Hauser T, et al.; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–220.
   PubMed Web of Science ®Google Scholar
• Edwards JCW, Szczepański L, Szechiński J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–2581.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al.; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–2806.
   PubMed Web of Science ®Google Scholar
• Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.
   PubMed Web of Science ®Google Scholar